Show simple item record

dc.contributor.authorNash, P
dc.contributor.authorSmolen, JS
dc.date.accessioned2021-03-18T06:26:17Z
dc.date.available2021-03-18T06:26:17Z
dc.date.issued2021
dc.identifier.issn0003-4967
dc.identifier.doi10.1136/annrheumdis-2021-219919
dc.identifier.urihttp://hdl.handle.net/10072/403276
dc.description.abstractWe thank Banday et al for their correspondence and their concise summary of information about monogenic interferonopathies and the response to various Jak inhibitors.1 As we have detailed in the paper, the Jakinib consensus statement and the associated systematic literature research2 3 focused on: Practical information for the clinician to assist with Jakinib therapy once the decision is made to prescribe a Jakinib no matter which disease indication exists such as those discussed in the correspondence. Entailed strict criteria for study inclusion which in particular excluded small cohort studies such as those quoted in the correspondence, moreover. Off label indications for Jakinib use such as the monogenic interferonopathies were also excluded pending future high quality randomised clinical trials (RCTs) for peer-reviewed assessment of Jakinib therapy, although understandably this is difficult in orphan diseases that are rare and meaningful numbers to study the efficacy and safety of any therapy is a real challenge. With respect to the interferonopathies, we cited three publications, including both sting-associated vasculopathy infantile onset (SAVI) syndrome and USP18 disease which are regarded as interferonopathies as mentioned by Banday et al In line with the conclusion in the correspondence that ‘the data are still not plentitude’, we look forward to future developments in this field and hope that these developments will lead to approval of Jakinibs for interferonopathies in the near future. Peter Nash and Josef S Smolen on behalf of the Jakinib Consensus group.
dc.languageeng
dc.publisherBMJ
dc.relation.ispartofjournalAnnals of the Rheumatic Diseases
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchImmunology
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode3204
dc.subject.keywordsbiological therapy
dc.subject.keywordsimmune system diseases
dc.subject.keywordstherapeutics
dc.titleResponse to: 'Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement'' by Banday et al
dc.typeJournal article
dc.type.descriptionC2 - Articles (Other)
dcterms.bibliographicCitationNash, P; Smolen, JS, Response to: 'Correspondence on 'Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement'' by Banday et al, Annals of the Rheumatic Diseases, 2021
dcterms.dateAccepted2021-02-17
dc.date.updated2021-03-18T06:21:05Z
gro.hasfulltextNo Full Text
gro.griffith.authorNash, Peter


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record